Why the study?
The clinical prognostic value of circulating lncRNA CARMN and its incremental effect when combined with conventional biomarkers in patients with acute myocardial infarction required investigation.
Does adding serum lncRNA CARMN to conventional biomarkers (cTnI, CK-MB) and echocardiographic LVEF improve the prediction of 6-month major adverse cardiovascular events (MACE) in patients with acute myocardial infarction undergoing PCI?
Cohort (n=215)
No
Does adding serum lncRNA CARMN to conventional biomarkers (cTnI, CK-MB) and echocardiographic LVEF improve the prediction of 6-month major adverse cardiovascular events (MACE) in patients with acute myocardial infarction undergoing PCI?
Answers are grounded in this paper and cite their sources.
Serum lncRNA CARMN is downregulated in acute myocardial infarction patients and, when combined with cTnI, CK-MB, and LVEF, significantly improves the prediction of 6-month major adverse cardiovascular events following PCI.
Background This study aims to explore the clinical value of lncRNA CARMN in acute myocardial infarction (AMI) patients. Methods The study subjects included 156 AMI patients and 59 healthy controls. The serum CARMN levels were detected by real-time quantitative polymerase chain reaction (RT-qPCR). The correlation between CARMN and myocardial injury markers, as well as cardiac ultrasound indicators by Pearson analysis. Kaplan–Meier and Cox regression were employed to screen out the independent influencing factors for MACE in AMI patients, and a nomogram was constructed. Results In patients with AMI, the serum CARMN level is decreased. CARMN level correlated with cTnI, CK-MB, Myo, LVEF. A total of 156 patients with AMI were enrolled and followed up for 6 months, among whom 60 patients experienced MACE. Lower CARMN levels were associated with a higher incidence of MACE. The AUC of the combined model for predicting MACE reaches 0.867, and the nomogram has good calibration and high clinical net benefit. Conclusion Serum CARMN combined with myocardial injury markers and ultrasound indicators, may help predict MACE risk in patients with AMI.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a cohort in Acute myocardial infarction (n=215). Serum lncRNA CARMN expression level vs. High CARMN expression / non-MACE group / healthy controls was evaluated on Major adverse cardiovascular events (composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, heart failure, or malignant arrhythmia) at 6 months (HR 0.049, 95% CI 0.012-0.200, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: